Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma - ScienceDirect
Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer: Trends in Pharmacological Sciences
Targeting Brd4 for cancer therapy: inhibitors and degraders - MedChemComm (RSC Publishing)
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma - Annals of Oncology
Frontiers | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases | Pharmacology
JQ1 - Wikipedia
Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction | Nature Communications
Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases | RMD Open
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study - The Lancet Haematology
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
Targeting Brd4 for cancer therapy: inhibitors and degraders - MedChemComm (RSC Publishing) DOI:10.1039/C8MD00198G
Clinical trials of bromodomain and extra-terminal inhibitors. | Download Table
Next-generation epigenetic inhibitors
Summary of BET inhibitor clinical trials (open Dec. 2017). | Download Table
Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases | RMD Open
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer - ScienceDirect
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence | Semantic Scholar
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
Drug Toxicities With BET Inhibitors in Clinical Trials a | Download Table
Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4 | Oncogenesis
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency - ScienceDirect
